Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Genmab expenses up in pursuit of preclinical advancement
September 2016
SHARING OPTIONS:

COPENHAGEN, Denmark—Genmab A/S recently reported revenue of kr524 million in H1 2016, an increase over the same period last year. Expenses were up as well, to kr366 million, which Genmab attributed to “the additional investment in our pipeline of products, including the advancement of tisotumab vedotin, HuMax-AXL-ADC, HexaBody-DR5/DR5, DuoBody-CD3xCD20 and our other preclinical programs.” The company accordingly revised its 2016 guidance for expected operating expenses, from the range of kr775 million to kr825 million up to kr800 million to kr850 million. Genmab is looking to advance several preclinical products, and boasts more than 30 of them in its pipeline. The company noted in a recent presentation that its 2016 goals include progressing its HexaBody-DR5/DR5 program and its preclinical DuoBody and HexaBody projects.
 
“Four key projects—Tissue Factor-ADC, AXL-ADC, DR5 and CD3-CD20—account for about kr320 million of our total expenses in 2016,” David Eatwell, Genmab’s chief financial officer, said on a conference call.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.